Skip to main content

Table 2 Summary of available best evidence on APTC events

From: Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk

Treatment Best evidence source [reference] Patient years of exposure Number of events APTC(% per year)
Placebo Meta-analysis of celecoxib trials [19] 585 8 1.40
Placebo Meta-analysis of etoricoxib trials [34] 335 4 1.20
Placebo Meta-analysis of lumiracoxib trials [20] 614 6 1.00
Placebo Meta-analysis of rofecoxib trials [32] 1678 32 1.90
Placebo Meta-analysis of valdecoxib trials [33] 161 2 1.25
Celecoxib Meta-analysis of celecoxib trials [19] 5651 57 1.10
Etoricoxib Meta-analysis of etoricoxib trials [23, 34] 30404 277 0.91
Lumiracoxib Meta-analysis of lumiracoxib trials [20] 7859 72 0.92
Rofecoxib Meta-analysis of rofecoxib trials [32] 6556 78 1.19
Valdecoxib Meta-analysis of valdecoxib trials [33] 1340 17 1.27
NSAID Meta-analysis of celecoxib trials [19] 4386 54 1.20
NSAID Meta-analysis of etoricoxib trials [23, 34] 27644 232 0.80
NSAID Meta-analysis of lumiracoxib trials [20] 6805 55 0.82
NSAID Meta-analysis of rofecoxib trials [32] 4726 41 0.87
NSAID Meta-analysis of valdecoxib trials [33] 656 13 1.97
  1. APTC – Antiplatelet Triallists Collaboration outcome of fatal and nonfatal heart attack or stroke, and cardiovascular death